InMed Pharmaceuticals Inc. (INM) · Nov 3, 2026 · Material agreement

InMed earnings flag cash crunch before Mentari merger vote

$490M merger financing — $490M expected financing; cash runway only into mid-November

InMed’s earnings update keeps the Mentari merger on track, but highlights a thin cash runway and unresolved Nasdaq compliance risk.

InMed is no longer primarily an operating biotech story; it is a cash-constrained vehicle awaiting a reverse merger that would replace its legacy pipeline with Mentari’s migraine-prevention programs. The merger, planned $490 million financing and November 4 shareholder vote were already disclosed before this release, so the filing mainly confirms the existing transition rather than creating a new one.

The strategic pivot is still on schedule, but not completed. InMed continues to target a fourth-quarter 2026 closing, with the combined company expected to operate as Mentari Therapeutics and pursue a new Nasdaq ticker. 〔0〕 The $490 million financing would give the successor company substantial development capital, but that capital is conditional on the transaction closing rather than available to InMed today.

The immediate problem is liquidity, not pipeline progress. Cash fell to $1.0 million from $2.2 million at June 30, while management says available cash funds planned operations only into mid-November. 〔1〕 That creates a narrow bridge between the November 4 vote and the expected closing, leaving little room for delay or additional spending.

Nasdaq has bought the deal more time, not removed the listing risk. InMed’s shareholders’ equity was $1.075 million versus the $2.5 million minimum, and Nasdaq granted until March 15, 2027, to regain compliance. The proposed merger and financing are the intended solution, so the extension helps operationally but does not change the fact that the central fix remains contingent.

FigureQ1 FY2027Comparison
R&D expense (Financial Commentary)$0.2M$0.6M Q1 FY2026
Cash and equivalents (Financial Commentary)$1.0M$2.2M Jun. 30, 2026
Shareholders’ equity (Nasdaq compliance)$1.075M$2.5M minimum
Expected Mentari financing (Corporate Update)~$490M—

Bottom line: This is a confirmation of the planned merger path, not a fresh business breakthrough. The financing could reset InMed’s story if the deal closes, but the current company remains financially tight and dependent on that closing happening soon.

What to watch next

Nov. 4 shareholder vote on Mentari merger

Original filing on SEC EDGAR

InMed earnings flag cash crunch before Mentari merger vote | INM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.